Profile data is unavailable for this security.
About the company
Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.
- Revenue in HKD (TTM)340.57m
- Net income in HKD-354.21m
- Incorporated2018
- Employees477.00
- LocationOcumension TherapeuticsNo. 1858 Yinzhongnan RoadGuoxiang Subdistrict, Wuzhong DistrictSUZHOU KY1-1205ChinaCHN
- Websitehttps://www.ocumension.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Golden Throat Holdings Group Co Ltd | 1.10bn | 287.80m | 2.33bn | 860.00 | 8.09 | 1.65 | 7.05 | 2.11 | 0.3893 | 0.3893 | 1.49 | 1.90 | 0.4994 | 3.23 | 4.07 | 1,270,917.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
Cutia Therapeutics | 218.26m | -575.51m | 3.98bn | 360.00 | -- | 3.04 | -- | 18.23 | -1.89 | -1.89 | 0.7171 | 4.28 | 0.1206 | 2.31 | 6.93 | 732,407.40 | -31.81 | -- | -35.82 | -- | 50.33 | -- | -263.68 | -- | 4.82 | -- | 0.1818 | -- | 1,110.83 | -- | -253.30 | -- | -- | -- |
Jiangsu Recbio Technology Co Ltd | 0.00 | -602.06m | 4.30bn | 507.00 | -- | 4.64 | -- | -- | -1.26 | -1.26 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -25.33 | -- | -32.84 | -- | -- | -- | -- | -- | 0.9619 | -- | 0.4548 | -- | -- | -- | 20.86 | -- | -- | -- |
Ocumension Therapeutics | 340.57m | -354.21m | 4.40bn | 477.00 | -- | 1.47 | -- | 12.93 | -0.5404 | -0.5404 | 0.5194 | 4.38 | 0.103 | 2.40 | 2.48 | 767,048.60 | -10.71 | -38.78 | -11.55 | -41.47 | 58.29 | 62.30 | -104.01 | -975.82 | 5.00 | -- | 0.0055 | -- | 54.99 | -- | 5.68 | -- | 319.66 | -- |
Beijing Luzhu Biotechnology Co Ltd | 0.00 | -307.25m | 4.98bn | 148.00 | -- | 4.84 | -- | -- | -1.52 | -1.52 | 0.00 | 5.12 | 0.00 | -- | -- | 0.00 | -23.80 | -- | -25.44 | -- | -- | -- | -- | -- | 5.91 | -- | 0.0296 | -- | -- | -- | 65.62 | -- | -- | -- |
Shandong Boan Biotechnology Co Ltd | 790.07m | 67.84m | 5.31bn | 777.00 | 74.32 | 3.30 | 36.86 | 6.72 | 0.1332 | 0.1332 | 1.55 | 3.00 | 0.3069 | 1.10 | 2.60 | 971,800.90 | 2.63 | -- | 3.43 | -- | 74.10 | -- | 8.59 | -- | 1.03 | 4.01 | 0.3369 | -- | 19.80 | -- | 64.02 | -- | -- | -- |
Consun Pharmaceutical Group Ltd | 3.01bn | 918.01m | 6.59bn | 3.18k | 6.85 | 1.62 | 6.56 | 2.19 | 1.14 | 1.14 | 3.73 | 4.81 | 0.5209 | 2.00 | 12.89 | 961,378.10 | 15.97 | 12.04 | 23.24 | 19.25 | 74.22 | 74.55 | 30.66 | 24.89 | 2.80 | -- | 0.1144 | 40.84 | 10.71 | 7.03 | 14.88 | 11.01 | -22.93 | 18.43 |
Data as of Oct 10 2024. Currency figures normalised to Ocumension Therapeutics's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Temasek Holdings Pte Ltd. (Investment Management)as of 15 Jul 2024 | 41.44m | 5.97% |
Capital Research & Management Co. (World Investors)as of 06 Dec 2023 | 34.37m | 4.95% |
Zhong Geng Fund Management Co. , Ltd.as of 31 Dec 2023 | 21.38m | 3.08% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 9.36m | 1.35% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 4.99m | 0.72% |
Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 3.10m | 0.45% |
FIL Investment Management (Hong Kong) Ltd.as of 30 Jun 2024 | 2.60m | 0.38% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 2.14m | 0.31% |
UBS Asset Management (Hong Kong) Ltd.as of 30 Apr 2024 | 2.04m | 0.29% |
Dimensional Fund Advisors LPas of 04 Jul 2024 | 1.92m | 0.28% |
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.